Trevena, Inc. (NASDAQ:TRVN) Short Interest Up 114.3% in May

Trevena, Inc. (NASDAQ:TRVN) saw a significant growth in short interest in the month of May. As of May 31st, there was short interest totalling 43,500 shares, a growth of 114.3% from the May 15th total of 20,300 shares. Approximately 0.2% of the company’s shares are short sold. Based on an average daily volume of 172,900 shares, the days-to-cover ratio is currently 0.3 days.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on TRVN shares. HC Wainwright reduced their target price on Trevena from $9.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, May 16th. StockNews.com started coverage on Trevena in a research report on Sunday. They issued a “sell” rating on the stock.

Institutional Investors Weigh In On Trevena

An institutional investor recently bought a new position in Trevena stock. Jump Financial LLC bought a new position in shares of Trevena, Inc. (NASDAQ:TRVN) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 44,396 shares of the biopharmaceutical company’s stock, valued at approximately $27,000. Jump Financial LLC owned approximately 0.32% of Trevena at the end of the most recent reporting period. Institutional investors and hedge funds own 13.56% of the company’s stock.

Trevena Trading Up 1.7 %

NASDAQ:TRVN traded up $0.01 on Thursday, reaching $0.39. The company’s stock had a trading volume of 15,612 shares, compared to its average volume of 143,288. The company has a quick ratio of 3.60, a current ratio of 3.60 and a debt-to-equity ratio of 8.35. The firm has a market cap of $7.22 million, a price-to-earnings ratio of -0.15 and a beta of 1.07. Trevena has a 12-month low of $0.30 and a 12-month high of $1.12. The stock has a 50 day moving average price of $0.40 and a 200 day moving average price of $0.53.

Trevena (NASDAQ:TRVN) last posted its quarterly earnings data on Wednesday, May 15th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.01. The firm had revenue of $0.02 million during the quarter. On average, equities analysts anticipate that Trevena will post -1.29 EPS for the current fiscal year.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.